# Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

> **NCT03444038** · PHASE2 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 85 (actual)

## Conditions studied

- Tourette Syndrome

## Interventions

- **DRUG:** Valbenazine

## Key facts

- **NCT ID:** NCT03444038
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-08
- **Primary completion:** 2019-07-12
- **Final completion:** 2019-07-12
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2022-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03444038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03444038, "Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03444038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*